Table 1 Baseline characteristics of participants in the modified full-analysis cohort
Group A (two doses primed + Convidecia, n = 96) | Group B (two doses primed + CoronaVac, n = 102) | Group C (one dose primed + Convidecia, n = 51) | Group D (one dose primed + CoronaVac, n = 50) | |
|---|---|---|---|---|
Age in years (%) | ||||
18–50 | 67 (69.8) | 69 (67.7) | 37 (72.6) | 39 (78.0) |
51–59 | 29 (30.2) | 33 (32.4) | 14 (27.5) | 11 (22.0) |
Median age (IQR) | 47.0 (40.3, 51.0) | 47.0 (41.0, 52.0) | 47.0 (35.0, 51.0) | 43.5 (38.5, 49.3) |
Sex (%) | ||||
Male | 58 (60.4) | 64 (62.8) | 27 (52.9) | 30 (60.0) |
Female | 38 (39.6) | 38 (37.3) | 24 (47.1) | 20 (40.0) |
Baseline neutralizing antibody against SARS-CoV-2 (%)a | ||||
Negative | 70 (72.9) | 90 (88.2) | 48 (94.1) | 48 (96.0) |
Positive | 26 (27.1) | 12 (11.8) | 3 (5.9) | 2 (4.0) |
Ethnicity | ||||
Han | 96 (100) | 102 (100) | 51 (100) | 50 (100) |
Time since the last priming dose of inactivated vaccine (months) | ||||
Median (IQR) | 3.2 (3.2, 4.6) | 3.3 (3.2, 4.6) | 1.8 (1.8, 1.8) | 1.8 (1.8, 1.8) |
Pre-existing AD5-neutralizing antibodies (%) | ||||
Participants with titer ≤ 1:200 | 27 (28.1) | 38 (37.3) | 19 (37.3) | 15 (30.0) |
Participants with titer > 1:200 | 69 (71.9) | 64 (62.7) | 32 (62.7) | 35 (70.0) |
